Dechra increases its 2018 full year dividend by 18.9%
Dechra Pharmaceuticals 2018 final results
Strong financial performance:
Revenue growth of 13.9% to £407.1 million.
Underlying operating profit growth of 24.0% to £99.2 million.
Underlying EBIT margin expansion of 200 bps to 24.4%.
Underlying diluted EPS increased by 20.9% to 76.45 pence.
Full year dividend of 25.50 pence, up 18.9%.
Shoe Zone 2018 final results
Workspace 2019 interim resultsRead more
Avon Rubber 2018 final resultsRead more
Adept technology 2019 interim resultsRead more
Land Securities 2018 interim resultsRead more
B&M European value retail 2019 interim resultsRead more
Softcat 2018 final resultsRead more
Bellway 2018 final resultsRead more